Armata Pharmaceuticals(US:ARMP) Prnewswire·2025-10-22 15:10Core Insights - Armata Pharmaceuticals has reported positive results from its Phase 2a diSArm study of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025 [1][2][3] Study Overview - The diSArm study was a randomized, double-blind, controlled trial comparing AP-SA02 combined with best available antibiotic therapy (BAT) against a placebo group receiving BAT alone [2][14] - A total of 42 patients were enrolled, with 29 receiving AP-SA02 and 13 receiving placebo, with methicillin-resistant S. aureus (MRSA) identified in approximately 38% of both groups [4][14] Efficacy Results - At day 12, clinical response rates were significantly higher in the AP-SA02 group, with 88% responding compared to 58% in the placebo group (p = 0.047) [6][17] - No patients in the AP-SA02 group experienced non-response or relapse at one week post-BAT or at the end of the study, while the placebo group had a non-response/relapse rate of approximately 25% [7][17] Safety Profile - AP-SA02 was well-tolerated, with treatment-emergent adverse events occurring in 6% of patients in the AP-SA02 group compared to 0% in the placebo group [8][17] - Serious adverse events related to the study drug were not reported [8] Mechanism and Future Directions - The study highlighted the potential of AP-SA02's defined genomic variants to provide rapid, strain-specific responses to S. aureus isolates, suggesting a flexible and adaptive therapeutic approach [10][17] - The results support advancing AP-SA02 into a pivotal Phase 3 trial planned for 2026, pending FDA review [17] Company Background - Armata Pharmaceuticals focuses on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections, with a pipeline that includes candidates for various pathogens [16] - The Phase 1b/2a study was partially funded by a $26.2 million award from the Department of Defense [15]